Summary
Pharma stocks, specifically Caplin Point and Natco Pharma, are under scrutiny following U.S. FDA inspections that resulted in observations at their facilities. While Caplin Point received 10 procedural observations, Natco Pharma received four at its Visakhapatnam plant, with experts noting that the severity depends on the nature of the observations and the companies' corrective actions.